filgrastim-sndz
US Court blocks Novartis biosimilar Neupogen
May 8, 2015Sales and Marketing Neupogen, Novartis, Zarxio, biosimilar, filagrastim, filgrastim-sndz
Novartis have been temporarily prevented from marketing its biosimilar version of Amgen’s drug Neupogen in the US. Earlier this year …
Novartis secures first US biosimilar product
March 6, 2015Research and Development, Sales and Marketing Amgen, Cancer, FDA, Neupogen, Novartis, Sandoz, Zarxio, biosimilar, filgrastim-sndz
Novartis’ generic arm Sandoz has won the race to become the first company to market a biosimilar in the US …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
